Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.
about
Validation of full-field optical coherence tomography in distinguishing malignant and benign tissue in resected pancreatic cancer specimens.Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-AnalysisMinimally invasive pancreatic cancer surgery: What is the current evidence?Chemotherapy and tumor microenvironment of pancreatic cancer.Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial.Is Adjuvant Therapy Necessary for All Patients with Localized Pancreatic Cancer Who Have Received Neoadjuvant Therapy?Evolving treatment landscape for early and advanced pancreatic cancer.Current and future therapies for advanced pancreatic cancer.Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review.Postoperative Adjuvant Therapy for Resectable Pancreatic Cancer With Gemcitabine and Adoptive Immunotherapy.Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer.Time to Initiation of Adjuvant Chemotherapy in Pancreas Cancer: A Multi-Institutional Experience.Systemic Combination Chemotherapy in Elderly Pancreatic Cancer: a Review.Oncolytic viral therapy for pancreatic cancer.The pancreatic cancer microenvironment: A true double agent.Neoadjuvant treatment for borderline and resectable pancreatic ductal adenocarcinoma.Adjuvant treatment for pancreatic ductal carcinoma.Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients.Prognostic value of microRNA expression levels in pancreatic adenocarcinoma: a review of the literature.Germline mutations in pancreatic cancer and potential new therapeutic options.Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival.Clinical Trials in Pancreatic Cancer: A Long Slog.Long noncoding RNA NORAD, a novel competing endogenous RNA, enhances the hypoxia-induced epithelial-mesenchymal transition to promote metastasis in pancreatic cancer.Is Neoadjuvant Therapy Sufficient in Resected Pancreatic Cancer Patients? A National Study.Pancreatic ductal adenocarcinoma in 2017: Time to change the therapeutic algorithm?Association of Adjuvant Therapy with Improved Survival in Ampullary Cancer: A National Cohort Study.AFAP1-AS1: A novel oncogenic long non-coding RNA in human cancers.T-Helper 1 Immune Response in Metastatic Lymph Nodes of Pancreatic Ductal Adenocarcinoma: A Marker For Prolonged Survival.Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions.Contemporary Management of Localized Resectable Pancreatic Cancer.Pancreaticoduodenectomy for periampullary tumours: a review article based on Surveillance, End Results and Epidemiology (SEER) database.A look at the progress of treating pancreatic cancer over the past 20 years.Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy.Lipid Metabolism and Lipid Droplets in Pancreatic Cancer and Stellate Cells.Identification of Educational Gaps Among Oncologists Who Manage Patients with Pancreatic Cancer.The clinical benefit of hyperthermia in pancreatic cancer: a systematic review.Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study.Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty.Defining the molecular pathology of pancreatic body and tail adenocarcinoma.The Multidisciplinary Approach to Localized Pancreatic Adenocarcinoma.
P2860
Q33570699-746E05E0-9C6F-464C-8D36-68A74BEFDDFFQ33754779-B29F6CCA-C7AA-4EEC-8D35-01BEC06A69D1Q33840638-6F369E51-0D3C-4C77-BF14-9B9976F41DA3Q33876637-698F939C-387B-4118-921D-380E5677A4A7Q38371662-E593DCB7-4429-4221-AB50-C1E08EACFABFQ38604399-E2C29C9F-311C-4AE4-84B9-84687081DDF9Q38624806-51B44A3F-1ED5-44E4-81BD-1AA530763573Q38673621-9CC23C49-26E1-45D0-861F-C2B625B7040FQ38678790-132C5762-D185-4714-A2DF-394E9215B736Q38697560-640DD90D-3DA6-4092-9BFE-D19E8A302DA8Q38722475-C711FE25-A1D1-4362-9AD5-DFA79FE681FEQ38732870-9804E317-1B13-4845-9E6B-233C8D51F302Q38902171-075F024C-3D5A-4EBD-8C6A-38774893CDD2Q39240683-9D1FCC1D-ABF9-4078-9E6A-675915E26670Q39366753-85D49A42-35C5-402C-BBDA-4178F32D6595Q39371358-8A17FBCE-ABA2-4303-BD0C-1F8F21EECDABQ39389872-9980FC93-D2BF-4FB0-8784-02CB78CF2B82Q42374126-299830F5-9569-4F9C-861C-8255E7B340A8Q42700661-D8B70C23-A86C-448C-9070-3B3686C73851Q42700671-53DE3A07-5B61-402C-BAFF-B308AB0A5146Q45304734-30184722-36F3-4259-ACB6-DE1EE957B23BQ47095955-4E0E63E7-3F18-41DE-80BA-8223FC07A9A2Q47144639-E73360CC-99D7-4167-81B8-633B7DC6719DQ47319862-4F78EAA1-EF6B-4775-886C-AF8038229C40Q47553858-43E06A15-9CCF-4FD4-B17D-879E2B3E57F7Q47614694-B639FCB6-9B7E-4F56-BE7C-E25CA6085112Q47618652-77984B05-C504-4A1C-9A47-0F0ACB254B0EQ47619850-6B279EEC-634D-4844-AFA9-10EC65505499Q47701382-5D59E89D-650D-4216-A3C7-4C0E2711CF2CQ47716584-2F66988B-0C5E-428D-BF69-0E406FC56568Q47730990-0876FEB5-4958-4FE0-A3AE-CBAAEE933DB6Q47731653-C619F1FF-DBC4-43DF-A2D5-BF0D3F08B6F0Q47735303-2429651F-2DF8-4EB5-B3DF-C2CA8E71F353Q47754576-541801CE-AB9F-4BD1-A8EF-2A6379D80CF3Q47816414-057DD8CC-62D4-498C-A5C5-E4CC0FFCCC60Q47822083-99B7DBBB-AE40-41B2-B8F5-13F3395C04A1Q48169834-67518089-FC24-44B2-8E69-02C1D526D7C3Q48221094-7C285F70-904E-48D7-B0DD-A0D076DF8085Q48229462-B7B37248-416C-4B06-A8D1-34FC3045D935Q48599351-66DFB1F9-79B9-4FEC-ADF6-63EA975711A4
P2860
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Comparison of adjuvant gemcita ...... el, randomised, phase 3 trial.
@en
type
label
Comparison of adjuvant gemcita ...... el, randomised, phase 3 trial.
@en
prefLabel
Comparison of adjuvant gemcita ...... el, randomised, phase 3 trial.
@en
P2093
P50
P1154
2-s2.0-85011349966
P1433
P1476
Comparison of adjuvant gemcita ...... el, randomised, phase 3 trial.
@en
P2093
Alan Anthoney
Alec McDonald
Christopher M Halloran
Daniel H Palmer
David Borg
David Sherriff
Derek A O'Reilly
Eftychia E Psarelli
European Study Group for Pancreatic Cancer
Gary William Middleton
P304
P356
10.1016/S0140-6736(16)32409-6
P407
P5530
P577
2017-01-24T00:00:00Z
P6179
1074196849